PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-25 (29)
 

Clipboard (0)
None
Journals
Year of Publication
Document Types
1.  Immune Evasion by Chimeric Trachea 
The New England journal of medicine  2010;362(2):172-174.
doi:10.1056/NEJMe0908366
PMCID: PMC4045014  PMID: 20071709
2.  TREM2 and Neurodegenerative Disease 
The New England journal of medicine  2013;369(16):1564-1565.
doi:10.1056/NEJMc1306509#SA1
PMCID: PMC3980568  PMID: 24131184
3.  Weighing the Benefits and Burdens of Witnessed Resuscitation 
The New England journal of medicine  2013;368(11):1058-1059.
doi:10.1056/NEJMe1300397
PMCID: PMC3601383  PMID: 23484835
4.  Increasing Options for the Treatment of Osteoporosis 
The New England journal of medicine  2009;361(8):818-820.
doi:10.1056/NEJMe0905480
PMCID: PMC3901579  PMID: 19671654
5.  Current and Future Therapies for Hepatitis C Virus Infection 
The New England journal of medicine  2013;369(7):10.1056/NEJMc1307589.
doi:10.1056/NEJMc1307589
PMCID: PMC3878654  PMID: 23944318
6.  Diagnosis of Smoldering Multiple Myeloma 
The New England journal of medicine  2011;365(5):474-475.
doi:10.1056/NEJMc1106428
PMCID: PMC3773467  PMID: 21812699
7.  The Tumor Lysis Syndrome 
The New England journal of medicine  2011;365(6):571-574.
doi:10.1056/NEJMc1106641#SA1
PMCID: PMC3740722  PMID: 21830982
8.  The spindle assembly checkpoint, aneuploidy and gastrointestinal cancer 
The New England journal of medicine  2010;363(27):2665-2666.
doi:10.1056/NEJMe1008017
PMCID: PMC3731131  PMID: 21190461
9.  PARP and Cancer — If It's Broke, Don't Fix It 
The New England journal of medicine  2011;364(3):277-279.
doi:10.1056/NEJMe1012546
PMCID: PMC3712751  PMID: 21208102
10.  Prostate Cancers in Men with Low PSA Levels — Must We Find Them? 
The New England journal of medicine  2004;350(22):2292-2294.
doi:10.1056/NEJMe048003
PMCID: PMC3474980  PMID: 15163780
11.  Expanding Treatment Options for Metastatic Prostate Cancer 
The New England journal of medicine  2011;364(21):2055-2058.
doi:10.1056/NEJMe1102758
PMCID: PMC3458507  PMID: 21612475
12.  Personalized Medicine and Inhibition of EGFR Signaling in Lung Cancer 
The New England Journal of Medicine  2009;361(10):1018-1020.
doi:10.1056/NEJMe0905763
PMCID: PMC3390194  PMID: 19692681
13.  Immunosuppressive Therapy and Tolerance of Organ Allografts 
The New England journal of medicine  2008;358(4):407-411.
doi:10.1056/NEJMe0707578
PMCID: PMC2980288  PMID: 18216363
14.  Failure to Validate Association between 12p13 Variants and Ischemic Stroke 
The New England journal of medicine  2010;362(16):1547-1550.
doi:10.1056/NEJMc0910050
PMCID: PMC2978046  PMID: 20410525
15.  Interleukin-2 Therapy in Patients with HIV Infection 
The New England journal of medicine  2010;362(3):270-271.
BACKGROUND
Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clinical implication of these increases is not known.
METHODS
We conducted two trials: the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT) study and the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT). In each, patients infected with the human immunodeficiency virus (HIV) who had CD4+ cell counts of either 50 to 299 per cubic millimeter (SILCAAT) or 300 or more per cubic millimeter (ESPRIT) were randomly assigned to receive interleukin-2 plus antiretroviral therapy or antiretroviral therapy alone. The interleukin-2 regimen consisted of cycles of 5 consecutive days each, administered at 8-week intervals. The SILCAAT study involved six cycles and a dose of 4.5 million IU of interleukin-2 twice daily; ESPRIT involved three cycles and a dose of 7.5 million IU twice daily. Additional cycles were recommended to maintain the CD4+ cell count above predefined target levels. The primary end point of both studies was opportunistic disease or death from any cause.
RESULTS
In the SILCAAT study, 1695 patients (849 receiving interleukin-2 plus antiretroviral therapy and 846 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 202 cells per cubic millimeter were enrolled; in ESPRIT, 4111 patients (2071 receiving interleukin-2 plus antiretroviral therapy and 2040 receiving antiretroviral therapy alone) who had a median CD4+ cell count of 457 cells per cubic millimeter were enrolled. Over a median follow-up period of 7 to 8 years, the CD4+ cell count was higher in the interleukin-2 group than in the group receiving antiretroviral therapy alone — by 53 and 159 cells per cubic millimeter, on average, in the SILCAAT study and ESPRIT, respectively. Hazard ratios for opportunistic disease or death from any cause with interleukin-2 plus antiretroviral therapy (vs. antiretroviral therapy alone) were 0.91 (95% confidence interval [CI], 0.70 to 1.18; P = 0.47) in the SILCAAT study and 0.94 (95% CI, 0.75 to 1.16; P = 0.55) in ESPRIT. The hazard ratios for death from any cause and for grade 4 clinical events were 1.06 (P = 0.73) and 1.10 (P = 0.35), respectively, in the SILCAAT study and 0.90 (P = 0.42) and 1.23 (P = 0.003), respectively, in ESPRIT.
CONCLUSIONS
Despite a substantial and sustained increase in the CD4+ cell count, as compared with antiretroviral therapy alone, interleukin-2 plus antiretroviral therapy yielded no clinical benefit in either study. (ClinicalTrials.gov numbers, NCT00004978 [ESPRIT] and NCT00013611 [SILCAAT study].)
doi:10.1056/NEJMc0910951
PMCID: PMC2869083  PMID: 20089981
17.  Unorthodox Approach to the Development of a New Antituberculosis Therapy 
The New England journal of medicine  2009;360(23):2466-2467.
doi:10.1056/NEJMe0903012
PMCID: PMC2787472  PMID: 19494223
18.  More on HIV-Associated Kaposi’s Sarcoma 
The New England journal of medicine  2008;358(5):535-536.
doi:10.1056/NEJMc072994
PMCID: PMC2857919  PMID: 18234764
19.  Metabolic Enzymes as Oncogenes or Tumor Suppressors 
The New England journal of medicine  2009;360(8):813-815.
doi:10.1056/NEJMe0810213
PMCID: PMC2848669  PMID: 19228626
20.  Brown Adipose Tissue — When It Pays to Be Inefficient 
The New England journal of medicine  2009;360(15):1553-1556.
doi:10.1056/NEJMe0900466
PMCID: PMC2753374  PMID: 19357412
21.  Renal Phosphate–Transporter Regulatory Proteins and Nephrolithiasis 
The New England journal of medicine  2008;359(11):1171-1173.
doi:10.1056/NEJMe0805943
PMCID: PMC2738939  PMID: 18784108
23.  Cancer Immunotherapy: The End Game Begins 
The New England journal of medicine  2008;358(25):2664-2665.
doi:10.1056/NEJMp0803663
PMCID: PMC2728623  PMID: 18565858
24.  Identifying and Addressing Safety Signals in Clinical Trials 
The New England journal of medicine  2008;359(13):1400-1402.
doi:10.1056/NEJMe0807372
PMCID: PMC2703718  PMID: 18768938
25.  TLR Polymorphisms and the Risk of Invasive Fungal Infections 
The New England journal of medicine  2008;359(17):1836-1838.
doi:10.1056/NEJMe0806412
PMCID: PMC2630794  PMID: 18946070

Results 1-25 (29)